The Spectrum of Fungal Colonization and Their Attributable Effects on Cystic Fibrosis Patients with Rare CFTR Genetic Mutations

Chronic airway colonization by bacteria and fungi is very common in CF patients, causing irreversible lung damage. It is known that rates of fungal infections are much lower than those of bacterial infections, however they can worsen the medical condition of CF patients. In this study, we identify t...

Full description

Bibliographic Details
Published in:	Microbiology Research
Main Authors:	Merlin Thomas, Soha Aboukhalaf, Toqa Darwish, Menatalla Ali, Omar Elsaied, Mutaz Al Bakri, Mostafa Najim, Mohamed M. Emara, Mona Al Langawi
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Subjects:	cystic fibrosis CF I1234V CFTR mutation fungal colonization bronchial asthma pancreatic insufficiency
Online Access:	https://www.mdpi.com/2036-7481/12/3/42

Similar Items

Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions
by: Samer Hammoudeh, et al.
Published: (2019-10-01)

Cystic Fibrosis - a very common genetic disease among the population - a general review
by: Julia Rutkowska, et al.
Published: (2023-06-01)

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR
by: Iwona Pranke, et al.
Published: (2025-10-01)

A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators
by: Chiara Lanfranchi, et al.
Published: (2024-10-01)

Targeting CFTR Ubiquitination: Current Advances in Therapeutic Strategies for Cystic Fibrosis
by: Yuka Kamada, et al.
Published: (2026-05-01)

Cystic fibrosis mutation spectrum in north macedonia: A step toward personalized therapy
by: Terzic M, et al.
Published: (2019-08-01)

Cystic Fibrosis-Screening Positive Inconclusive Diagnosis: Newborn Screening and Long-Term Follow-Up Permits to Early Identify Patients with CFTR-Related Disorders
by: Alice Castaldo, et al.
Published: (2020-08-01)

F1099L-CFTR (c.3297C>G) has Impaired Channel Function and Associates with Mild Disease Phenotypes in Two Pediatric Patients
by: Xiaoying Zhang, et al.
Published: (2021-02-01)

CFTR mutations and phenotypic correlations in people with cystic fibrosis: a retrospective study from a single centre in south IndiaResearch in context
by: Sneha D. Varkki, et al.
Published: (2024-08-01)

Cystic fibrosis therapy: from symptoms to the cause of the disease
by: T N. Kireeva, et al.
Published: (2025-04-01)

CFTR Modulator Therapy for Rare CFTR Mutants
by: Marco Mergiotti, et al.
Published: (2022-04-01)

Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome
by: Mohini A. Gunnett, et al.
Published: (2023-03-01)

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
by: Virginia Spanò, et al.
Published: (2021-02-01)

CFTR High Expresser Cells in cystic fibrosis and intestinal diseases
by: Diego Carlos dos Reis, et al.
Published: (2023-03-01)

NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis
by: Chiara Brandas, et al.
Published: (2021-09-01)

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
by: Ryosuke Fukuda, et al.
Published: (2020-04-01)

One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies
by: Marjolein M. Ensinck, et al.
Published: (2022-06-01)

Cross‐talk between CFTR and sphingolipids in cystic fibrosis
by: Dorina Dobi, et al.
Published: (2023-09-01)

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
by: Isabelle Sermet-Gaudelus
Published: (2013-03-01)

CFTR and Ca2+ signaling in cystic fibrosis
by: Fabrice eAntigny, et al.
Published: (2011-10-01)

Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders
by: Moshirfar M, et al.
Published: (2022-11-01)

Decreasing Poly(ADP-ribose) Polymerase activity restores ΔF508 CFTR trafficking
by: Suzana Maria Anjos, et al.
Published: (2012-09-01)

CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells
by: Virginia Lotti, et al.
Published: (2022-04-01)

Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators
by: Michela Francalanci, et al.
Published: (2023-01-01)

Frequency of CFTR variants in southern Brazil and indication for modulators therapy in patients with cystic fibrosis
by: Eliandra da Silveira Lima, et al.
Published: (2021-12-01)

Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
by: Burkhard Tümmler, et al.
Published: (2025-05-01)

CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
by: Francesca Saluzzo, et al.
Published: (2022-04-01)

Early developmental phenotypes in the cystic fibrosis sheep model
by: Arnaud J. Van Wettere, et al.
Published: (2023-01-01)

Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children With Cystic Fibrosis: A Meta-Analysis
by: Qiyu Li, et al.
Published: (2022-06-01)

Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation
by: Óscar Fonseca, et al.
Published: (2023-02-01)

Impact of Airway Inflammation on the Efficacy of CFTR Modulators
by: Carla M. P. Ribeiro, et al.
Published: (2021-11-01)

Increased prevalence of CFTR variants and susceptibility to CRS: A real-world study based on Chinese children
by: Yang Han, et al.
Published: (2024-04-01)

CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways
by: Min Wu, et al.
Published: (2024-04-01)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
by: Julian Berges, et al.
Published: (2023-05-01)

Characterization of two rat models of cystic fibrosis—KO and F508del CFTR—Generated by Crispr‐Cas9
by: Elise Dreano, et al.
Published: (2019-12-01)

Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programmeResearch in context
by: Pierre-Régis Burgel, et al.
Published: (2025-10-01)

Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells
by: Paolo Scudieri, et al.
Published: (2020-09-01)

Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice
by: Barbara Dhooghe, et al.
Published: (2015-07-01)

Two years of newborn screening for cystic fibrosis in North Macedonia: First experience
by: Fustik S, et al.
Published: (2021-07-01)

The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review
by: Isabelle R. McKay, et al.
Published: (2022-06-01)